BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 24, Issue 40
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (12651)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.
Item 
Count 
PDF1046
WORD292
HTML7524
Figures (1-1)540
Tables (1-1)535
 Sum=9937
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse901
Download1806
 Sum=2707
Oct 28, 2018 (publication date) through Apr 17, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2018; 24(40): 4548-4553
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4548
Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
Te-Fu Lin, Ping-I Hsu
Te-Fu Lin, Ping-I Hsu, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
Author contributions: Hsu PI designed the study, reviewed the articles and drafted the manuscript; Lin TF reviewed the articles and drafted the manuscript.
Conflict-of-interest statement: Both authors have no conflicts of interest.
Correspondence to: Ping-I Hsu, MD, Attending Doctor, Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Rd, Kaohsiung 813, Taiwan. williamhsup@yahoo.com.tw
Telephone: +886-7-3468233 Fax: +886-7-3468237
Received: August 7, 2018
Peer-review started: August 7, 2018
First decision: August 27, 2018
Revised: September 20, 2018
Accepted: October 5, 2018
Article in press: October 5, 2018
Published online: October 28, 2018
Processing time: 80 Days and 22.2 Hours
Core Tip

Core tip: The present article reviews current second-line anti-Helicobacter pylori (H. pylori) regimens. Bismuth quadruple therapy and levofloxacin-amoxicillin triple therapy have comparable eradication rates in the rescue treatment of H. pylori infection, while the former has more adverse effects than the latter. High-dose dual therapy has an eradication rate comparable with levofloxacin-amoxicillin triple therapy. Ten-day tetracycline-levofloxacin quadruple therapy achieves a markedly higher eradication rate compared with levofloxacin-amoxicillin triple therapy (98% vs 69%) in patients with failure of standard triple, bismuth quadruple or non-bismuth quadruple therapy. In conclusion, tetracycline-levofloxacin quadruple therapy has the potential to become a universal second-line treatment for H. pylori infection.
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345